Identification, characterization, and screening of monoclonal antibodies for the treatment of ? and ?-light chain amyloidosis and drug discovery for ALECT2 amyloidosis. Potential candidates will be sc...
Paradox Immunotherapeutics Incorporated
3 enregistrements totalisant 287,119.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $287,119 | 3 enregistrements |
Enregistrements
Paradox Immunotherapeutics Incorporated
$183,595.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2022-2023
Canada
Paradox Immunotherapeutics Incorporated
$73,524.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2024-2025
Canada
As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly...
Paradox Immunotherapeutics Incorporated
$30,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Youth Employment Program
EF 2022-2023
Canada
AL amyloidosis is a life-threatening disease caused by the misfolding of free immunoglobulin light chains (LC) which deposit as light chain amyloid (AL) in the heart, kidney, and nervous system, causi...